Boston Partners increased its position in Laboratory Corporation of America Holdings (NYSE:LH) by 4.8% during the second quarter, Holdings Channel reports. The fund owned 4,590,372 shares of the medical research company’s stock after buying an additional 210,138 shares during the period. Laboratory Corporation of America Holdings comprises approximately 0.9% of Boston Partners’ holdings, making the stock its 23rd largest position. Boston Partners’ holdings in Laboratory Corporation of America Holdings were worth $707,560,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. CFO4Life Group LLC acquired a new stake in Laboratory Corporation of America Holdings during the first quarter worth $312,000. Oxford Asset Management boosted its stake in Laboratory Corporation of America Holdings by 68.6% in the first quarter. Oxford Asset Management now owns 51,622 shares of the medical research company’s stock worth $7,406,000 after buying an additional 21,003 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in Laboratory Corporation of America Holdings by 2.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 9,900 shares of the medical research company’s stock worth $1,420,000 after buying an additional 199 shares in the last quarter. Elkfork Partners LLC boosted its stake in Laboratory Corporation of America Holdings by 2.4% in the first quarter. Elkfork Partners LLC now owns 12,936 shares of the medical research company’s stock worth $1,856,000 after buying an additional 308 shares in the last quarter. Finally, Toronto Dominion Bank boosted its stake in Laboratory Corporation of America Holdings by 55.5% in the first quarter. Toronto Dominion Bank now owns 27,613 shares of the medical research company’s stock worth $3,961,000 after buying an additional 9,857 shares in the last quarter. 91.89% of the stock is owned by institutional investors and hedge funds.

Laboratory Corporation of America Holdings (LH) opened at 157.75 on Thursday. The company has a market capitalization of $16.15 billion, a price-to-earnings ratio of 22.09 and a beta of 0.94. Laboratory Corporation of America Holdings has a 52-week low of $119.51 and a 52-week high of $164.22. The stock has a 50 day moving average price of $154.89 and a 200 day moving average price of $144.02.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, beating the Zacks’ consensus estimate of $2.40 by $0.07. The business had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.47 billion. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.36 earnings per share. Analysts anticipate that Laboratory Corporation of America Holdings will post $9.51 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/boston-partners-buys-210138-shares-of-laboratory-corporation-of-america-holdings-lh/1470264.html.

A number of equities research analysts recently weighed in on LH shares. ValuEngine cut Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a report on Saturday, June 3rd. Jefferies Group LLC dropped their price target on Laboratory Corporation of America Holdings from $159.00 to $157.00 and set a “hold” rating for the company in a report on Friday, April 28th. Barclays PLC raised their price target on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the company an “overweight” rating in a report on Thursday, July 27th. Zacks Investment Research cut Laboratory Corporation of America Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, April 19th. Finally, BidaskClub raised Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $158.42.

In other Laboratory Corporation of America Holdings news, insider Lisa J. Uthgenannt sold 5,000 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $160.00, for a total value of $800,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Lance Berberian sold 3,613 shares of the stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $139.84, for a total transaction of $505,241.92. Following the completion of the sale, the senior vice president now owns 5,789 shares of the company’s stock, valued at approximately $809,533.76. The disclosure for this sale can be found here. Insiders have sold a total of 14,581 shares of company stock worth $2,256,899 in the last three months. Insiders own 0.90% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.